This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rose, P. G. Search for Related Content PubMed PubMed Citation Articles by Rose, P. G.

Original Paper Gynecologic Oncology

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA

Correspondence: Peter G. Rose, M.D., Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A-81, Cleveland, Ohio 44195, USA. Telephone: 216-444-1712; Fax: 216-444-8551; e-mail: rosep{at}ccf.org

The need for effective, well-tolerated, and convenient therapies for patients with advanced ovarian cancer has led researchers to continually refine chemotherapeutic regimens to balance efficacy with safety and tolerability in order to maintain or improve patient quality of life. In this article, we review current strategies for the optimal dosing of pegylated liposomal doxorubicin (DOXIL^®; Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.tibotec.com; Caelyx^®, Schering-Plough Corporation, Kenilworth, NJ, http://www.sch-plough.com) in relapsed ovarian cancer. Pegylated liposomal doxorubicin has demonstrated efficacy in the treatment of recurrent/resistant ovarian cancer in several clinical trials utilizing a dose of 50 mg/m² every 4 weeks. The most common adverse events associated with pegylated liposomal doxorubicin treatment in these studies—hand-foot syndrome (HFS, also known as palmar-plantar erythrodysesthesia) and stomatitis—are schedule and dose dependent, respectively, and do not typically lead to discontinuation of therapy. Several phase II and retrospective studies support the use of pegylated liposomal doxorubicin 40 mg/m² every 4 weeks (dose intensity of 10 mg/m² weekly) to optimize clinical efficacy and minimize the occurrence of schedule- and dose-related adverse events in patients with recurrent/relapsed ovarian cancer. Further reductions in dose intensity are necessary for use in combined chemotherapy regimens. Antitumor activity was maintained, with reduced incidences of HFS and stomatitis. Given the chronic course of ovarian cancer, the improved tolerability profile of pegylated liposomal doxorubicin 40 mg/m² combined with a convenient once-monthly dosing schedule may translate into an improved quality of life for patients with ovarian cancer.

Key Words. Doxorubicin • Liposomes • Ovarian neoplasms • Drug administration schedules

This article has been cited by other articles:

				W. C. Zamboni Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents Oncologist, March 1, 2008; 13(3): 248 - 260. [Abstract] [Full Text] [PDF]

				A. Chan, V. Shih, and T. Chee Kian Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 105 - 107. [Abstract] [PDF]

				W. C. Zamboni Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents Clin. Cancer Res., December 1, 2005; 11(23): 8230 - 8234. [Full Text] [PDF]